Innovation in Space: Paul Kamoun on SpacePharma’s Breakthroughs in Microgravity Research and Collaboration with Evolution Europe

In this insightful interview, we speak with Paul Kamoun, Managing Director of SpacePharma’s European branch, about the company’s groundbreaking work in space-based pharmaceutical research. 

With a focus on their innovative Spactory project and the unique advantages of microgravity research, Paul shares valuable insights into how SpacePharma is pushing the boundaries of science and manufacturing. He also discusses their collaboration with Evolution Europe and provides practical advice for startups seeking funding through the EIC Accelerator. Read more to explore the exciting future of space-based life sciences and the strategic moves shaping SpacePharma’s success.

1.Could you explain what Spacepahrma’s Spactory is and how it works?

SpacePharma has developed miniaturized, remotely controlled space labs for life science and health R&D, and we’re now moving towards large-scale production in space. The Spactory will be the first space-based factory to produce active pharmaceutical ingredients, focusing initially on antibodies. It has two main components: setting up the factory infrastructure and developing the technology for antibody production in microgravity, which could improve the quality and effectiveness of medicines.

2. How does lab research in space work, and what specific benefits does microgravity offer over Earth-based research?

Lab research in microgravity offers unique advantages. The absence of gravity affects physical and chemical processes, allowing for the creation of materials and products that can’t be made on Earth. For instance, molecules behave differently, which can lead to new discoveries in chemistry and biology. This environment helps us understand gene expression and bacterial behavior in ways not possible on Earth, leading to innovations in pharmaceuticals, materials science, and biotechnology.

3. What potential breakthroughs in drug discovery and development do you anticipate as a result of microgravity research?

Microgravity research could lead to breakthroughs across several fields. In pharmaceuticals, we can create new types of protein crystals and enhance drug formulations. For cosmetics, accelerated aging in space allows for faster development of anti-aging products. In regenerative medicine, space provides an ideal environment for 3D bioprinting tissues and organs. While our initial focus is on antibodies, the potential applications are vast, touching on various scientific and medical fields.

4. Is there a specific topic that you’re focusing your first research on?

Our first focus is on monoclonal antibodies, which are crucial for treating many diseases, especially cancer. The market for these therapies is substantial, making it a strategic priority both medically and commercially. While monoclonal antibodies are our initial focus, our space-based research has the potential to impact many other areas.

5. Could you share with us your experience collaborating with Evolution to secure funding?

Evolution Europe has a highly skilled team that quickly understands new challenges and turns them into clear, competitive proposals. Their approach is designed to produce successful proposals, providing support from start to finish in a professional and user-friendly manner. Their expertise in translating complex science into effective proposals was essential for securing our funding.

While our project was strong, Evolution’s deep knowledge of EU programs, especially the EIC Accelerator, made a significant difference. Having previously applied on our own without success, working with Evolution had a substantial impact. Their help with proposal writing, interview preparation, and overall guidance was excellent, and we believe we couldn’t have succeeded without their support.

6. How does SpacePharma address the logistical and regulatory challenges associated with conducting experiments and manufacturing in space?

Addressing logistical and regulatory challenges is critical. We work closely with the European Medicines Agency (EMA) and the European Space Agency to develop procedures for space-based production and ensure compliance with regulations. Space introduces complexities, such as legal frameworks and intellectual property issues, which are guided by international agreements. Aligning our processes with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards is a significant but ongoing effort.

7. Now that you have funding, what are the next steps for SpacePharma in this project?

With funding secured, we plan to increase our flight frequency from about three times a year to once a month or more. This is made possible by new space vehicles becoming available. In the short term, we’ll focus on using these new opportunities to advance our research and production. Long-term, we aim to drive innovation in health and life sciences through space research, which offers significant potential for breakthroughs and benefits to humanity.

8. What advice would you give other startups and SMEs applying for the EIC Accelerator?

For startups and SMEs applying for the EIC Accelerator, my advice is to use all available support. We had strong technology and strategy, but Evolution Europe’s help was needed to make our proposal successful. Their expertise in translating complex science into compelling proposals and their support in writing, interview preparation, and video production were key. Partnering with experts like Evolution Europe can greatly enhance your chances of success.